LIESTAL, SWITZERLAND--(Marketwire - September 28, 2007) - Initiation of a six month study with 51 FRDA patients and ICARS as primary endpoint expected shortly. Fast-track designation granted by FDA.
LIESTAL, SWITZERLAND--(Marketwire - September 28, 2007) - Initiation of a six month study with 51 FRDA patients and ICARS as primary endpoint expected shortly. Fast-track designation granted by FDA.
